This is a rare genetic condition that increases the risk of developing certain types of cancer. It's caused by a specific change in a gene called p53, which helps protect cells from damage. People with this syndrome are more likely to get cancers like breast cancer, soft tissue sarcomas, brain tumors, osteosarcoma, leukemia, and adrenal cancer.
Every report comes from a Lived member, sent anonymously.
Have you had Prophylactic Mastectomy for Li-Fraumeni Syndrome?
Li-Fraumeni syndrome (LFS) is a rare inherited condition that greatly raises the risk of developing cancer, often at a young age. It is caused by a change in a gene called TP53. That gene normally acts as a safeguard inside cells, stopping or repairing cells whose DNA has been damaged before they can grow into a tumor. When one copy of the gene does not work, that safeguard is weaker throughout the body. The cancers most closely linked to LFS are breast cancer in young women, bone cancer (osteosarcoma), soft tissue sarcomas (cancers of muscle, fat and other connective tissue), brain tumors and adrenocortical carcinoma, a rare cancer of the outer layer of the adrenal glands that sit on top of the kidneys. Leukemia and several other cancers also occur more often. Some appear in early childhood, others in adulthood, and people with LFS can develop more than one cancer over their lifetime. LFS itself causes no symptoms. It is a predisposition, so a person feels nothing until a cancer develops. Estimates suggest it affects roughly 1 in 5,000 to 1 in 20,000 people. Because carriers are now often found without a striking family history, specialists increasingly use the broader name heritable TP53-related cancer syndrome.
LFS follows an autosomal dominant pattern: one altered copy of TP53 is enough to raise cancer risk, and a parent who carries it has a 50 percent chance of passing it to each child. Most people inherit it from a parent, but in roughly 7 to 20 percent the change is new in that person, so LFS can appear in someone with no family history of cancer. Inheriting the change does not mean cancer is certain or that it will follow the same pattern as in a relative. Cancer starts when the remaining working copy of TP53 is also lost in a particular cell. Early studies, drawn from families with many cancers, estimated a lifetime risk of 73 to 100 percent by age 70; specialists now believe those figures overstate the risk for many carriers. The specific gene change matters: some are strongly linked to childhood cancers, while others mainly raise the risk of cancers in adulthood. Women carry a very high risk of breast cancer, often before age 31, whereas men do not have a known increase in breast cancer risk. Radiation is one outside factor that matters. In people with LFS, radiation therapy and some chemotherapy drugs that work by damaging DNA appear to contribute to new, separate cancers later on. Nothing a person did caused the gene change itself.
LFS is confirmed with a genetic test, usually on a blood sample, that looks for a disease-causing change in TP53. Testing is ideally done with a genetic counselor, who explains what a result would mean for the person and their relatives before the test. Doctors consider testing when a family has several of the core LFS cancers at young ages, when one person has had more than one of those cancers, or when someone has a cancer that is strongly tied to LFS regardless of family history. Examples include adrenocortical carcinoma, choroid plexus carcinoma (a rare childhood brain tumor) and breast cancer before age 31. Once a family's specific change is known, adult relatives can be tested for that exact change. Whether to test children depends on whether the family's change is linked to childhood cancers, and the decision includes weighing the burden and uncertain benefits of screening a child from infancy. Results are not always simple. Many TP53 changes are single-letter spelling changes whose effect is uncertain, and interpreting them takes specialist expertise. A TP53 change found in only a small fraction of blood cells may come from age-related changes in blood cells or from a tumor rather than from an inherited condition, so results like these need confirmation before anyone is labeled as having LFS.
There is no treatment that corrects the inherited gene change. Care focuses on finding cancers early, when they are easier to treat, and on choosing cancer treatments that do not add to future risk. The main tool is lifelong surveillance, often called the Toronto protocol. For adults, current guidelines recommend a yearly physical exam, a yearly whole-body MRI (magnetic resonance imaging, a scan that uses magnets rather than radiation), a yearly brain MRI until about age 50 and, for women, a yearly breast MRI from age 20 to 65. For children whose family change is linked to childhood cancers, guidelines recommend a physical exam and abdominal ultrasound every six months, along with yearly whole-body and brain MRI from the first year of life. Because radiation may itself contribute to cancer in LFS, scans that use radiation, such as CT (computed tomography) and PET-CT (positron emission tomography combined with CT), are avoided where another test can answer the question. In one long-term study, people who chose surveillance and later developed cancer had five-year survival of about 89 percent, compared with about 60 percent among those who did not use surveillance. That study was observational, so it suggests rather than proves the benefit. Because breast cancer risk starts so early, some women choose risk-reducing mastectomy, surgery to remove the breasts before cancer develops. It is a personal decision with physical and emotional trade-offs, and its long-term survival benefit in LFS has not yet been measured. If cancer does develop, knowing about LFS before treatment begins changes the plan. Where possible, the care team favors surgery and avoids radiation therapy and DNA-damaging chemotherapy, since these contribute to later cancers. When radiation or chemotherapy is the best option for a particular cancer, it is still used.
LFS is lifelong, and so is surveillance. Most people have scans and checkups on a regular schedule for the rest of their lives, with the plan shifting as children become adults and as new evidence refines which tests are useful at which ages. Surveillance does find cancers before symptoms appear, but it is imperfect. Scans sometimes show findings that need a biopsy and turn out to be harmless, and a cancer can still develop between scheduled scans. The outlook varies widely. It depends on the specific gene change, which cancers develop and how early they are found. Many cancers found through surveillance can be treated successfully. Because more than 40 percent of carriers develop a second, separate cancer, surveillance continues after cancer treatment ends. Living with LFS affects more than physical health. Ongoing scans, waiting for results and worry about children or other relatives can be a real strain, and conversations about genetic testing can be hard within families. Genetic counseling, care at a center experienced in LFS, mental health support and connection with other families can help people and their relatives manage the practical and emotional load over time.
Ask for a genetic counseling referral if you have had one of the core LFS cancers at a young age, have had more than one of them, or have several close relatives with these cancers at young ages. If a relative has tested positive, talk with a genetic counselor about testing for yourself and, where appropriate, your children. If you already know you have LFS, contact your care team promptly about a new symptom rather than waiting for the next scheduled scan, since cancers can develop between scans. Important examples are a new lump anywhere, persistent bone pain or swelling, and, in a young child, signs of early puberty or unusual body hair, acne or voice deepening, which can point to an adrenal tumor. Always tell any doctor ordering a scan or planning cancer treatment that you have LFS, so they can choose options that limit radiation.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Li-Fraumeni Syndrome is like, what's helped you, or ask the community a question.